YOU CAN DISCOVER A WEALTH OF PSYCHEDELIC RESEARCH HERE

1. Sentinel Research Article: Magnesium-Ibogaine Therapy for TBI, PTSD, and Substance Misuse Disorder.

The January 2024 issue of Nature Medicine features an important study on magnesium-ibogaine therapy for treating traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), and substance use disorder. This research involved 30 male veterans with mild TBI and looked at the effectiveness of the Magnesium-Ibogaine: the Stanford Traumatic Injury to the CNS protocol (MISTIC), which includes magnesium and ibogaine treatment. The results showed significant improvements in functioning, PTSD, depression, and anxiety right after treatment and one month later. These findings suggest that magnesium-ibogaine therapy could be a promising new option for these complex issues, but more controlled trials are needed to confirm these early results.

Magnesium–ibogaine Therapy in Veterans with Traumatic Brain Injuries.

2. This article is an editorial statement published in the Journal of the American Medical Association from August 2023.

Psychedelic Therapy—A New Paradigm of Care for Mental Health | Psychiatry and Behavioral Health | JAMA | JAMA Network

3. This article is from Cambridge University Press dated 2021.

Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review | BJPsych Open | Cambridge Core

4. This 2021 article is from the esteemed journal Nature.

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study | Nature Medicine

5. Feeling disconnected is linked to mental suffering. This article examines developing a scale to measure connectedness to self, others, and world, hypothesizing improvements correlate with better mental health after psychedelic use.

The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world

6. This article is from the Journal of Psychopharmacology dated 2022.

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.

7. This article examines the efficacy of Psilocybin Vs. Escalopram in treating clinical depression is from The New England Journal of Medicine 2021.

Trial of Psilocybin versus Escitalopram for Depression | New England Journal of Medicine (nejm.org)

8. Psychedelics relax high-level beliefs, enhancing bottom-up information flow, potentially revising mental health, political, religious, and philosophical perspectives.

REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics

9. Psychedelics and nature reduce negative thoughts, enhance mindfulness and connectedness, improving mental health via complementary psychological benefits.

The Potential Synergistic Effects Between Psychedelic Administration and Nature Contact for the Improvement of Mental Health

10. This landmark study was published in Psychopharmacology in 2006 demonstrated the safety and enduring positive effects of a single dose of psilocybin.

“Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance”

11. This study showed significant reductions in depression and anxiety in cancer patients following psilocybin treatment.

“Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial” .

12. Another article from the Journal of Psychopharmacology.

“Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial”

13. Promising tobacco cessation research from the Journal of Psychopharmacology.

“Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction”.